Deutsche Bank's research report on Aegerion Pharmaceuticals provides an update following discussions with the company's management. The report highlights an increase in SG&A expenses for 2014, reflecting the company's strategy to invest in sales and marketing. The company aims to become profitable in the second half of 2014. The report also discusses the company's focus on customer care, expected reimbursement negotiations in the EU, and adjustments to financial models, including a revised price target of $115.00. The report reiterates a 'Buy' rating for Aegerion.
documents/vol00010-efta01461186-pdf.pdf
{"title":"Deutsche Bank Markets Research - Aegerion Alert","key_people":["Robyn Kamauskas","Alethia Young"],"document_date":"2013-11-18","document_type":"financial","key_locations":["United States","European Union"],"document_subtype":"Company Research Report","key_organizations":["Deutsche Bank","Aegerion Pharmaceuticals"],"reference_numbers":["DB-SDNY-0123054","SDNY_GM_00269238","EFTA01461186"]}